RT Journal Article
SR Electronic
T1 Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6593
OP 6599
VO 37
IS 12
A1 JASMINE M. MANOUCHEHRI
A1 MICHAEL KALAFATIS
YR 2017
UL http://ar.iiarjournals.org/content/37/12/6593.abstract
AB Background/Aim: Triple-negative breast cancer (TNBC) is the most fatal form of breast cancer due to the shortcomings of therapies. However, recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is a promising anticancer therapeutic that possesses the capability to promote the induction of apoptosis in cancer cells, but some TNBCs are resistant to rhTRAIL's pro-apoptotic effects. Therefore, a combinatorial treatment approach with silibinin and rhTRAIL was considered in order to sensitize rhTRAIL-resistant TNBCs. Materials and Methods: The co-treatment of rhTRAIL and silibinin's impact on apoptosis induction in rhTRAIL-resistant TNBC BT-20 and HCC1937 cells was inspected via application of Annexin V/PI assays and western blot analysis. Results: Silibinin possessed the ability to sensitize the examined rhTRAIL-resistant TNBC cells to rhTRAIL-induced apoptosis through the up-regulation of death receptors 4 and 5 and the down-regulation of survivin transcriptionally. Conclusion: Silibinin is a good sensitizing agent for rhTRAIL-resistant TNBCs.